Stereotaxis Inc
STXS at a Glance
- Next report
- Nov 10, 2026
NYSE MKT: STXS
About Stereotaxis
Stereotaxis (NYSE: STXS) is a surgical robotics company focused on minimally invasive endovascular intervention. The company develops and commercializes robotic systems, instruments, and digital solutions for the interventional laboratory. Its product portfolio includes the GenesisX robotic system, Synchrony digital operating room systems, and MAGiC robotic catheters. Following its acquisition of Robocath, Stereotaxis now covers the full spectrum of endovascular procedures, extending beyond its core electrophysiology market. The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and other regions. Stereotaxis generates revenue from system sales and a recurring base of disposables, service, and accessories. Updated
Frequently Asked Questions
What does Stereotaxis do?
Stereotaxis (NYSE: STXS) is a surgical robotics company focused on minimally invasive endovascular intervention. The company develops and commercializes robotic systems, instruments, and digital solutions for the interventional laboratory.